The efficacy of combination immunotherapy with ipilimumab plus nivolumab in metastatic myxofibrosarcoma

被引:0
作者
Kalofonou, Foteini [1 ,2 ]
Napolitano, Andrea [1 ,2 ]
Benson, Charlotte [1 ,2 ]
Miah, Aisha [1 ,2 ]
Zaidi, Shane [1 ,2 ]
Lindsay, Daniel [1 ,2 ]
Thway, Khin [1 ,2 ]
Jones, Robin L. [1 ,2 ]
机构
[1] Royal Marsden Hosp, Sarcoma Unit, London SW3 6JJ, England
[2] Inst Canc Res, London SW3 6JJ, England
关键词
rare tumors; combination immunotherapy; immunotherapy outcome; myxofibrosarcoma; ipilimumab; nivolumab; SOFT-TISSUE SARCOMA; OPEN-LABEL;
D O I
10.1177/20363613241290788
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We present the case of a patient with Myxofibrosarcoma (MFS), a mesenchymal type of soft tissue sarcoma (STS) and the response to combination immunotherapy with anti PD-1 and anti-CTLA-4 therapy, following disease progression after Standard chemotherapy (SACT) and Radiotherapy (RT). We have shown a timeline of treatment and responses, as well as the overall safety profile and the management of immunotherapy related adverse events. This study demonstrates the potential of checkpoint inhibitors as therapeutic agents in the treatment of MFS.
引用
收藏
页数:6
相关论文
共 10 条
[1]   Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials [J].
D'Angelo, Sandra P. ;
Mahoney, Michelle R. ;
Van Tine, Brian A. ;
Atkins, James ;
Milhem, Mohammed M. ;
Jahagirdar, Balkrishna N. ;
Antonescu, Cristina R. ;
Horvath, Elise ;
Tap, William D. ;
Schwartz, Gary K. ;
Streicher, Howard .
LANCET ONCOLOGY, 2018, 19 (03) :416-426
[2]   Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report [J].
Lambden, Jason P. ;
Kelsten, Max F. ;
Schulte, Brian C. ;
Abbinanti, Susan ;
Hayes, John P. ;
Villaflor, Victoria ;
Agulnik, Mark .
ONCOLOGIST, 2021, 26 (07) :549-553
[3]   Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient A case report [J].
Luo, Yi ;
Li Min ;
Zhou, Yong ;
Tang, Fan ;
Lu, Minxun ;
Xie, Hongmei ;
Wang, Yitian ;
Duan, Hong ;
Zhang, Wenli ;
Tu, Chongqi .
MEDICINE, 2021, 100 (12) :E25262
[4]   A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas [J].
Monga, Varun ;
Skubitz, Keith M. ;
Maliske, Seth ;
Mott, Sarah L. ;
Dietz, Hilary ;
Hirbe, Angela C. ;
Van Tine, Brian A. ;
Oppelt, Peter ;
Okuno, Scott ;
Robinson, Steven ;
O'Connor, Madeline ;
Seetharam, Mahesh ;
Attia, Steven ;
Charlson, John ;
Agulnik, Mark ;
Milhem, Mohammed .
CANCERS, 2020, 12 (07) :1-10
[5]   Clinical and translational implications of immunotherapy in sarcomas [J].
Recine, Federica ;
Vanni, Silvia ;
Bongiovanni, Alberto ;
Fausti, Valentina ;
Mercatali, Laura ;
Miserocchi, Giacomo ;
Liverani, Chiara ;
Pieri, Federica ;
Casadei, Roberto ;
Cavaliere, Davide ;
Falbo, Pina Tiziana ;
Diano, Danila ;
Ibrahim, Toni ;
De Vita, Alessandro .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[6]  
Riedel RF, 2023, J CLIN ONCOL, V41
[7]   Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial [J].
Tawbi, Hussein A. ;
Burgess, Melissa ;
Bolejack, Vanessa ;
Van Tine, Brian A. ;
Schuetze, Scott M. ;
Hu, James ;
D'Angelo, Sandra ;
Attia, Steven ;
Riedel, Richard F. ;
Priebat, Dennis A. ;
Movva, Sujana ;
Davis, Lara E. ;
Okuno, Scott H. ;
Reed, Damon R. ;
Crowley, John ;
Butterfield, Lisa H. ;
Salazar, Ruth ;
Rodriguez-Canales, Jaime ;
Lazar, Alexander J. ;
Wistuba, Ignacio I. ;
Baker, Laurence H. ;
Maki, Robert G. ;
Reinke, Denise ;
Patel, Shreyaskumar .
LANCET ONCOLOGY, 2017, 18 (11) :1493-1501
[8]   Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives [J].
Vanni, Silvia ;
De Vita, Alessandro ;
Gurrieri, Lorena ;
Fausti, Valentina ;
Miserocchi, Giacomo ;
Spadazzi, Chiara ;
Liverani, Chiara ;
Cocchi, Claudia ;
Calabrese, Chiara ;
Bongiovanni, Alberto ;
Riva, Nada ;
Mercatali, Laura ;
Pieri, Federica ;
Casadei, Roberto ;
Lucarelli, Enrico ;
Ibrahim, Toni .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[9]  
Yamamoto N, 2022, J CLIN ONCOL, V40
[10]   Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression [J].
Zhou, Maggie ;
Bui, Nam ;
Lohman, Marta ;
van de Rjin, Matt ;
Hwang, Gloria ;
Ganjoo, Kristen .
CASE REPORTS IN ONCOLOGY, 2021, 14 (01) :459-465